Opendata, web and dolomites

DEALS

Biomarker assay development to expedite ALS experimental therapeutic advancement

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DEALS project word cloud

Explore the words cloud of the DEALS project. It provides you a very rough idea of what is the project "DEALS" about.

als    lack    weakness    benefit    treeway    interventions    breathing    monitoring    efficacy    paper    million    disease    ema    speed    tests    feasibility    proof    assay    amyotrophic    mission    market    accurate    diagnostic    clinical    muscle    moving    walking    revenues    dutch    sclerosis    final    therapy    medicinal    soon    lateral    detectable    successful    delay    developer    characterised    rare    progressive    additional    diseases    excluding    instrumental    25    sme    eradicate    speeding    economic    foreseen    tool    combination    symptom    perform    patients    speaking    therapeutic    wasting    progression    received    onset    orphan    initial    trials    spasticity    entrepreneurs    quick    deals    diagnosis    earlier    mostly    symptoms    practical    founded    respiratory    earth    assays    swallowing    designation    drug    14    slowing    time    die    difficulties    therapies    severely    2012    mainly    stem    gained    biomarkers    diagnosed   

Project "DEALS" data sheet

The following table provides information about the project.

Coordinator
TREEWAY B.V. 

Organization address
address: SEVILLAWEG 142
city: ROTTERDAM
postcode: 3047AL
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.treeway.nl/treeway-receive-h2020-grant-for-biomarker-feasibility-study
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TREEWAY B.V. NL (ROTTERDAM) coordinator 50˙000.00

Map

 Project objective

The unique Dutch SME Treeway B.V. was founded in 2012 by two highly experienced and successful entrepreneurs that both have been diagnosed with amyotrophic lateral sclerosis (ALS). It is Treeway’s mission to eradicate ALS from the face of the earth by speeding up ALS research and bringing new therapies in the market as soon as possible. Treeway already has one new therapy in clinical development, which has recently received EMA’s Orphan Medicinal Product Designation.

ALS is a rare disease that is characterised by muscle spasticity and rapidly progressive weakness due to muscle wasting. This results in difficulties in walking, moving, speaking, swallowing, and breathing. Most ALS patients die from respiratory failure within three years. ALS diagnosis currently is mainly aimed at excluding other diseases with similar symptoms. As a result there is a 9–14-month delay between symptom onset and final diagnosis of ALS. For similar reasons, there is also a lack of accurate and practical diagnostic tests for monitoring the benefit of potential therapeutic interventions for ALS. This is severely slowing down the progression of clinical drug development in this field.

As ALS drug developer, Treeway will greatly benefit from the availability of a (combination of) quick diagnostic assay(s) to be used in monitoring therapeutic efficacy in clinical trials. In addition, the ALS diagnostic tool may also proof to be instrumental for (speeding up) the initial diagnosis of the disease.

Therefore, within DEALS, Treeway will perform a mostly paper study to investigate the technical and economic feasibility of developing a quick and reliable diagnostic tool. These developments will be based on known and detectable biomarkers of the disease. Economic benefit will stem from the ability of the assays to enable earlier diagnosis and to speed up clinical drug development; per one month gained in development time for a new ALS drug, about €25 million additional revenues can be foreseen.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DEALS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DEALS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More